{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:40:57Z","timestamp":1790775657666,"version":"4.1.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,11,6]],"date-time":"2018-11-06T00:00:00Z","timestamp":1541462400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s10067-018-4355-0","type":"journal-article","created":{"date-parts":[[2018,11,6]],"date-time":"2018-11-06T04:28:08Z","timestamp":1541478488000},"page":"949-954","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["The effect of methotrexate versus other disease-modifying anti-rheumatic drugs on serum drug levels and clinical response in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5580-8387","authenticated-orcid":false,"given":"Ana","family":"Mart\u00ednez-Feito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chamaida","family":"Plasencia-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Navarro-Comp\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borja","family":"Hern\u00e1ndez-Breijo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda \u00c1ngeles","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Monjo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Nu\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Nozal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dora","family":"Pascual-Salcedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Balsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,6]]},"reference":[{"key":"4355_CR1","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1136\/annrheumdis-2014-206588","volume":"74","author":"EH Vogelzang","year":"2015","unstructured":"Vogelzang EH, Pouw MF, Nurmohamed M, Kneepkens EL, Rispens T, Wolbink GJ, Krieckaert CLM (2015) Adalimumab trough concentrations in patients with rheumatoid arthritis and psoriatic arthritis treated with concomitant disease-modifying antirheumatic drugs. Ann Rheum Dis 74:474\u2013475","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"4355_CR2","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1111\/bcp.12313","volume":"78","author":"D Ternant","year":"2014","unstructured":"Ternant D, Ducourau E, Perdriger A, Corondan A, Le Goff B, Devauchelle-Pensec V et al (2014) Relationship between inflammation and infliximab pharmacokinetics in rheumatoid arthritis. Br J Clin Pharmacol 78(1):118\u2013128","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"4355_CR3","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","volume":"76","author":"JS Smolen","year":"2017","unstructured":"Smolen JS, Landew\u00e9 R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, van Vollenhoven R, Aletaha D, Aringer M, Boers M, Buckley CD, Buttgereit F, Bykerk V, Cardiel M, Combe B, Cutolo M, van Eijk-Hustings Y, Emery P, Finckh A, Gabay C, Gomez-Reino J, Gossec L, Gottenberg JE, Hazes JMW, Huizinga T, Jani M, Karateev D, Kouloumas M, Kvien T, Li Z, Mariette X, McInnes I, Mysler E, Nash P, Pavelka K, Po\u00f3r G, Richez C, van Riel P, Rubbert-Roth A, Saag K, da Silva J, Stamm T, Takeuchi T, Westhovens R, de Wit M, van der Heijde D (2017) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 76(6):960\u2013977","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"4355_CR4","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.reuma.2016.10.002","volume":"13","author":"MA Mart\u00edn-mart\u00ednez","year":"2017","unstructured":"Mart\u00edn-mart\u00ednez MA, Gonzalez-crespo MR, Garc\u00eda-vicu R, Tornero-molina J, Fern\u00e1ndez-nebro A, Blanco-garc\u00eda FJ (2017) Recommendations by the Spanish Rheumatology Society for the management of patients diagnosed with rheumatoid arthritis who cannot be treated with methotrexate & patient with rheumatoid arthritis who cannot use methotrexate. Reumatol Clin 13(3):127\u2013138","journal-title":"Reumatol Clin"},{"issue":"3","key":"4355_CR5","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1136\/annrheumdis-2013-204172","volume":"74","author":"MF Pouw","year":"2015","unstructured":"Pouw MF, Krieckaert CL, Nurmohamed MT, Van Der Kleij D, Aarden L, Rispens T et al (2015) Key findings towards optimising adalimumab treatment: the concentration\u2013effect curve. Ann Rheum Dis 74(3):513\u2013518","journal-title":"Ann Rheum Dis"},{"key":"4355_CR6","unstructured":"Burmester G-R, Kivitz AJ, Kupper H, Arulmani U, Florentinus S, Goss SL et al (2015) Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial. Ann Rheum Dis 74(6):1037\u20131044"},{"key":"4355_CR7","doi-asserted-by":"crossref","unstructured":"Arnett FC, Edworthy SM, Bloch DA, Mcshane DJ, Fries JF, Cooper NS, et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31(3):315\u201324","DOI":"10.1002\/art.1780310302"},{"issue":"1","key":"4355_CR8","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/art.1780390105","volume":"39","author":"AM Gestel van","year":"1996","unstructured":"van Gestel AM, Prevoo MLL, van\u2019t Hof MA, van Rijswijk MH, van de Putte LBA, van Riel PLCM (1996) Development and validation of the European league against rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization\/International League Against Rheumatism Cri. Arthritis Rheum 39(1):34\u201340","journal-title":"Arthritis Rheum"},{"key":"4355_CR9","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1093\/rheumatology\/ker124","volume":"50","author":"D Pascual-Salcedo","year":"2011","unstructured":"Pascual-Salcedo D, Plasencia C, Ramiro S, Nu\u00f1 OL, Bonilla G, Nagore D et al (2011) Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatology 50:1445\u20131452","journal-title":"Rheumatology"},{"key":"4355_CR10","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1136\/ard.2006.065615","volume":"66","author":"GM Bartelds","year":"2007","unstructured":"Bartelds GM, Wijbrandts CA, Nurmohamed MT (2007) Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 66:921\u2013926","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"4355_CR11","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","volume":"41","author":"RN Maini","year":"1998","unstructured":"Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD et al (1998) Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41(9):1552\u20131563","journal-title":"Arthritis Rheum"},{"key":"4355_CR12","doi-asserted-by":"crossref","unstructured":"D\u00e9nari\u00e9 D, Rinaudo-Gaujous M, Thomas T, Paul S, Marotte H (2017) Methotrexate reduced TNF bioactivity in rheumatoid arthritis patients treated with infliximab. Mediat Inflamm 2017:3708250","DOI":"10.1155\/2017\/3708250"},{"issue":"1","key":"4355_CR13","doi-asserted-by":"publisher","first-page":"75","DOI":"10.2174\/1874312901711010075","volume":"11","author":"J Teresa","year":"2017","unstructured":"Teresa J, Chamaida P-R, Ana M-F, Victoria N-C, Theo R, Annick V et al (2017) Predictive value of serum infliximab levels at induction phase in rheumatoid arthritis patients. Open Rheumatol J 11(1):75\u201387","journal-title":"Open Rheumatol J"},{"issue":"4","key":"4355_CR14","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1136\/ard.2010.139774","volume":"70","author":"MM Soliman","year":"2011","unstructured":"Soliman MM, Ashcroft DM, Watson KD, Lunt M, Symmons DPM, Hyrich KL (2011) Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 70(4):583\u2013589","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"4355_CR15","first-page":"431","volume":"35","author":"MJ L\u2019Ami","year":"2017","unstructured":"L\u2019Ami MJ, Kneepkens EL, Nurmohamed MT, Krieckaert CLM, Visman IM, Wolbink GJ (2017) Long-term treatment response in rheumatoid arthritis patients starting adalimumab or etanercept with or without concomitant methotrexate. Clin Exp Rheumatol 35(3):431\u2013437","journal-title":"Clin Exp Rheumatol"},{"key":"4355_CR16","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jim.2015.01.007","volume":"418","author":"K Bloem","year":"2015","unstructured":"Bloem K, van Leeuwen A, Verbeek G, Nurmohamed MT, Wolbink GJ, van der Kleij D, Rispens T (2015) Systematic comparison of drug-tolerant assays for anti-drug antibodies in a cohort of adalimumab-treated rheumatoid arthritis patients. J Immunol Methods 418:29\u201338","journal-title":"J Immunol Methods"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-018-4355-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-018-4355-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-018-4355-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,5]],"date-time":"2019-11-05T19:14:12Z","timestamp":1572981252000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-018-4355-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,6]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["4355"],"URL":"https:\/\/doi.org\/10.1007\/s10067-018-4355-0","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,6]]},"assertion":[{"value":"18 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the La Paz University Hospital Ethics Committee and all the patients signed an informed consent document.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}